Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 10/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7682920 | 0.78 | KDM4E (0.47) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| SCHEMBL7677673 | 0.78 | ALDH1A1 (0.47) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| SCHEMBL7677720 | 0.78 | AKR1B1 (0.60) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| SCHEMBL7683620 | 0.75 | KDM4E (0.45) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| SCHEMBL4816470 | 0.74 | KDM4E (0.44) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| Pterine SCHEMBL64321 | 0.73 | ALDH1A1 (0.41) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| Pterine SCHEMBL702492 | 0.72 | ALDH1A1 (0.40) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| Pterine SCHEMBL906055 | 0.72 | ALDH1A1 (0.40) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| Pterine SCHEMBL29287280 | 0.72 | ALDH1A1 (0.40) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| Pterine SCHEMBL5703599 | 0.72 | ALDH1A1 (0.40) | KDM4EALDH1A1HSD17B10LMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1978997-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | Apollo Life Sciences Limited (AU) | 2008-10-15 | — | — | EP | claimed |
| US-20070243132-A1 | Transdermal delivery of pharmaceutical agents | APOLLO LIFE SCIENCES LIMITED (AU) | 2007-10-18 | — | — | US | claimed |
| WO-2007070983-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | APOLLO LIFE SCIENCES LIMITED (AU) | 2007-06-28 | — | — | WO | claimed |
| US-12350271-B2 | Gamma polyglutamated aminopterin and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250213578-A1 | ALPHA POLYGLUTAMATED AMINOPTERIN AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-07-03 | — | — | US | disclosed |
| US-12310966-B2 | Alpha polyglutamated aminopterin and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-20210213019-A1 | GAMMA POLYGLUTAMATED AMINOPTERIN AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2021-07-15 | — | — | US | disclosed |
| US-20210052592-A1 | ALPHA POLYGLUTAMATED AMINOPTERIN AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2021-02-25 | — | — | US | disclosed |
| EP-3749320-A1 | ALPHA POLYGLUTAMATED AMINOPTERIN AND USES THEREOF | L.E.A.F Holdings Group LLC (US) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019157123-A1 | ALPHA POLYGLUTAMATED AMINOPTERIN AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC (US) | 2019-08-15 | — | — | WO | disclosed |
| WO-2009065181-A1 | NANOSTRUCTURES SUITABLE FOR DELIVERY OF AGENTS | APOLLO LIFE SCIENCES LIMITED (AU) | 2009-05-28 | — | — | WO | disclosed |
| WO-2008154705-A1 | TRANSDERMAL DELIVERY OF ACTIVE AGENTS | APOLLO LIFE SCIENCES LIMITED (AU) | 2008-12-24 | — | — | WO | disclosed |
| EP-1978997-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | Apollo Life Sciences Limited (AU) | 2008-10-15 | — | — | EP | disclosed |
| US-20070243132-A1 | Transdermal delivery of pharmaceutical agents | APOLLO LIFE SCIENCES LIMITED (AU) | 2007-10-18 | — | — | US | disclosed |
| WO-2007070983-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | APOLLO LIFE SCIENCES LIMITED (AU) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213578-A1 | ALPHA POLYGLUTAMATED AMINOPTERIN AND USES THEREOF | FOLH1, QPCT, SGTA | KDM4E 3931/4885ALDH1A1 4354/4885HSD17B10 3927/4885 |
| US-20210052592-A1 | ALPHA POLYGLUTAMATED AMINOPTERIN AND USES THEREOF | FOLH1, QPCT, SGTA | KDM4E 3931/4885ALDH1A1 4354/4885HSD17B10 3927/4885 |
| US-20210213019-A1 | GAMMA POLYGLUTAMATED AMINOPTERIN AND USES THEREOF | QPCT, SGTA, IFNG | KDM4E 4096/4885ALDH1A1 4591/4885HSD17B10 4033/4885 |
| US-12310966-B2 | Alpha polyglutamated aminopterin and uses thereof | FOLH1, QPCT, SGTA | KDM4E 3931/4885ALDH1A1 4354/4885HSD17B10 3927/4885 |
| US-12350271-B2 | Gamma polyglutamated aminopterin and uses thereof | QPCT, SGTA, IFNG | KDM4E 4096/4885ALDH1A1 4591/4885HSD17B10 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.